Response Biomedical launches COVID-19 (SARS-CoV-2) antigen test for countries accepting CE mark, to support the growing demand for testing.
Response Biomedical Corp. (Response), a global provider of acute care diagnostic testing solutions, announced today the launch of the RAMP® COVID-19 Antigen Test in countries that require CE marking. The CE Mark allows Response to market and sell the RAMP® COVID-19 Antigen Test to countries that recognize CE marking.
“The addition of the COVID-19 Antigen Test on the RAMP platform enhances our current offering of acute care tests that are already being used in the fight against COVID-19”, stated Dr. Barb Kinnaird, CEO of Response Biomedical. “We continue to be part of the global efforts against the pandemic and have scaled our manufacturing to cater to the ongoing growing demand for the acute care tests sold on our platform world-wide.”
The RAMP® instrument is a small, automated system capable of storing and transmitting results digitally. The RAMP® 200 offers complete traceability and reportability with the flexibility of running one to six tests at a time. In a method comparison study of 158 volunteers, the RAMP® COVID-19 Antigen Test showed 95% concordance with the leading U.S. antigen test.
The RAMP® COVID-19 Antigen Test uses the RAMP® 200 instrument for the detection of SARS-CoV-2 nucleoproteins in nasal swabs from individuals who are suspected of having COVID-19. The results are delivered in 15 minutes, enabling timely decision-making for healthcare professionals and on-site identification of COVID-19. The assay kit contains all components, including the swabs, allowing rapid triage of individuals suspected of SARS-CoV-2 infection.
About Response Biomedical Corporation
Response Biomedical Corp. (Response) is a Canadian manufacturer and global supplier of diagnostic tools that aid in the diagnosis of life-threatening diseases. Response focuses on providing lab quality results in minutes and our RAMP® technology delivers a total solution for making better, faster decisions. RAMP® tests are commercially available for the aid in early detection of heart attack, congestive heart failure, sepsis, thromboembolism, and pregnancy. The company is passionate about the patient’s experience and our core purpose to improve and save lives globally. For more information about Response, visit www.responsebio.com.